MedX’s DermSecure® Will Be Offered In Pharmacies & Medical Clinics in October
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Sep. 27, 2021--
MedX Health Corp. (“MedX” or the “Company”) (MDX - TSXV) and Vitamed Biomedical s.r.l. ("Vitamed") are pleased to announce a Memorandum of Understanding between the companies to pilot MedX’s leading-edge DermSecure® Screening Platform at select pharmacies and general practitioner (GP) clinics in Italy this October.
Europe continues to be a strong focus of MedX’s global commercialization strategy, following the ongoing success of its pilot program in the Netherlands. The MedX and Vitamed pilot program in Italy is expected to be in-market for 60 days from October to November 2021. Pending its successful completion, the MedX DermSecure® Screening Platform will become more widely available at pharmacies, GP clinics and insurance companies across Italy, as the next step in the commercialization strategy in this market. MedX will continue to build on this momentum with additional pilots anticipated later this year.